Genetic factors associated with small for gestational age birth and the use of human growth hormone in treating the disorder

Paul Saenger1* and Edward Reiter2

Abstract
The term small for gestational age (SGA) refers to infants whose birth weights and/or lengths are at least two standard deviation (SD) units less than the mean for gestational age. This condition affects approximately 3%–10% of newborns. Causes for SGA birth include environmental factors, placental factors such as abnormal uteroplacental blood flow, and inherited genetic mutations. In the past two decades, an enhanced understanding of genetics has identified several potential causes for SGA. These include mutations that affect the growth hormone (GH)/insulin-like growth factor (IGF)-1 axis, including mutations in the IGF-1 gene and acid-labile subunit (ALS) deficiency. In addition, select polymorphisms observed in patients with SGA include those involved in genes associated with obesity, type 2 diabetes, hypertension, ischemic heart disease and deletion of exon 3 growth hormone receptor (d3-GHR) polymorphism. Uniparental disomy (UPD) and imprinting effects may also underlie some of the phenotypes observed in SGA individuals. The variety of genetic mutations associated with SGA births helps explain the diversity of phenotype characteristics, such as impaired motor or mental development, present in individuals with this disorder. Predicting the effectiveness of recombinant human GH (hGH) therapy for each type of mutation remains challenging. Factors affecting response to hGH therapy include the dose and method of hGH administration as well as the age of initiation of hGH therapy. This article reviews the results of these studies and summarizes the success of hGH therapy in treating this difficult and genetically heterogenous disorder.

Keywords: Growth hormone, Small for gestational age, Insulin-like growth factor, Acid-labile subunit deficiency, Uniparental disomy

Definition and epidemiology of small for gestational age (SGA)
Despite past inconsistencies in defining small for gestational age (SGA) (as reviewed by Saenger et al [1]) the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society, as well as the International Small for Gestational Age Advisory Board, recently recommended that the term refer to infants whose birth weights and/or lengths are at least two standard deviation (SD) units less than the mean for gestational age [2,3]. According to this definition, approximately 3%–10% of newborns are considered SGA at birth, although it should be noted that new intrauterine growth curves created with a more contemporary, larger, and more racially diverse population suggest that many SGA patients are often misclassified as appropriate for gestational age (AGA) [4]. While most of these infants undergo catch-up growth, 10%–15% remain small for their age at the age of 2 years [5-8]. In 2001, human growth hormone (hGH) therapy using dose regimens up to 48 mcg/kg/week [3] was approved by the United States (US) Food and Drug Administration (FDA) to treat SGA patients greater than 2 years old. However, because the causes of SGA are diverse, hGH treatment outcomes vary among patients. Thus, identifying the underlying mechanisms for SGA births may help predict patient response to hGH therapy. Causes for SGA births, which are summarized in Table 1 [3,4], involve environmental factors, placental factors such as abnormal uteroplacental blood flow, or inherited genetic mutations [3,4]. Over the last two decades,
significant research related to genetic mutations that influence SGA has been conducted, and this article reviews the results of these studies and summarizes the success of hGH therapy in treating this condition. It should be mentioned at the beginning of this review, however, that the number of genetic variations for any particular gene that has been associated with SGA birth does not necessarily correlate with the number of patients who have this defect. For instance, four different genetic mutations in the distal region of the terminal long arm of chromosome 15 linked with SGA birth size will be described, while only two mutations are illustrated for patients born SGA with Silver-Russell syndrome (SRS). However, this does not mean that SGA patients are two times more likely to have a mutation in the distal region of chromosome 15 than a mutation associated with SRS. Of note, a website from the Growth Genetics Consortium, an international collaboration, gathers all current information about genetic syndromes disrupting the growth hormone and insulin-like growth factor (IGF) axis [9]. Cases reported involve the following genes: GHR, GHHR, STAT5B, IGF1, IGF2, IGFALS, and IGF1R. Forty-eight cases have been approved for inclusion into the database so far. This paper aims to illustrate the variety of genetic mutations that are associated with SGA births while concurrently describing how other phenotype characteristics of the patient, such as motor or mental development, can vary depending on which mutation was inherited.

**Genetic factors influencing SGA**

**GH/IGF-1 axis**

**IGF-1 gene**

Transcription of the gene for *IGF-1* is mediated by the binding of pituitary GH to specific GH receptors on hepatocytes. The secretion of IGF-1 from the liver then stimulates cell growth (particularly bone) and inhibits secretion of GH from the pituitary [10]. Consequently, mutations of the *IGF-1* gene affect growth and GH secretion and have been correlated with SGA births. A homozygous partial deletion of exons 4 and 5 of *IGF-1* was observed for one patient born SGA. The mutation truncated the IGF-1 peptide sequence from 70 to 25 amino acids and was followed by an out-of-frame nonsense sequence and stop codon. In addition to growth defects, the patient suffered from bilateral sensorineural deafness and mental retardation, a feature indicating the importance of IGF-1 in central nervous system development [11]. When treated with hGH at a 0.1 U/kg dose for 4 days, no detectable IGF-1 level could

---

**Table 1 Factors associated with increased incidence of SGA birth**

| Fetal | Maternal | Uterine/Placental | Demographic |
|-------|----------|-------------------|-------------|
| Karyotypic | Medical conditions | Gross structural placental factors | Maternal age |
| - Trisomy 21 | Hypertension | Single umbilical artery | - Very young age |
| - Trisomy 18 | Renal disease | Placental hemangiomas | - Older age |
| - Monosomy X | Diabetes mellitus | Infarcts, focal lesions | Maternal height |
| - Trisomy 13 | Collagen vascular diseases | Insufficient uteroplacental perfusion | Maternal weight |
| Chromosomal abnormalities | Maternal hypoxemia | Suboptimal implantation site | Maternal and paternal race |
| - Autosomal deletion | Infection | Placenta previa | History of SGA |
| - Ring chromosomes | Toxoplasmosis | Low-lying placenta | |
| Genetic diseases | Rubella | Placental abruption | |
| - Achondroplasia | Cytomegalovirus | |
| - Bloom syndrome | Herpesvirus | |
| Congenital anomalies | Malaria | |
| - Potter syndrome | Trypanosomiasis | |
| - Cardiac abnormalities | HIV | |
| Nutritional status | Low prepregnancy weight | |
| - Low pregnancy weight | |
| Substance use/abuse | Cigarette smoking | |
| - Alcohol | |
| - Illicit drugs | |
| - Therapeutic drugs | |

HIV, human immunodeficiency virus; SGA, small for gestational age.

Reprinted with permission from [3].
be observed in the patient. However, when treated with recombinant human IGF-1 (rhIGF-1) therapy for one year (three months at 40 mcg/kg/day, nine months at 80 mcg/kg/day), insulin sensitivity, bone mineral density, and line growth of this patient were improved [12].

A second patient born SGA with sensorineural deafness and mental retardation was evaluated for IGF-1 defects. Investigators observed a T→A transversion in the 3’-untranslated region of exon 6 that caused the expression of a truncated version of exon 6 and an altered E domain of the IGF-1 hormone. hGH therapy for this patient (200 mcg hGH/day intramuscular doses for seven days) afforded no improvement in IGF-1 levels [13]. It should be noted that a second research group later sequenced IGF-1 (exons 1–6) in 53 children born SGA and determined that none of the mutations in the coding region of IGF-1 correlate with SGA stature [14].

Similarly, an IGF-1 defect was observed for a third patient who had initially been evaluated at the age of 21 years for SGA birth size [15]. In addition to SGA size, the patient initially presented with bilateral hearing loss, microcephaly, and severe mental retardation. When investigators re-evaluated the patient at 55 years of age, unusually high serum levels of IGF-1 were noted, which varied from the patient phenotypes described by Woods and Bonapace [11-13]. Furthermore, both insulin-like growth factor binding protein-3 (IGFBP-3) and insulin-like growth factor-1 receptor (IGF-1R) levels were normal. However, by sequencing IGF-1, investigators detected a nucleotide substitution at position 274 (G→A) in the sequence, which caused an amino acid substitution at position 44 of the IGF-1 protein (V44M). The modified IGF-1 protein displayed a 90-fold-lower binding affinity for IGF-1R than the wild-type corresponding protein. This change resulted in diminished phosphorylation of IGF-1R and downstream-acting signaling proteins, particularly Akt/PKB [16,17].

Finally, when a fourth patient born SGA in length and weight was evaluated for IGF-1 defects, investigators discovered a homozygous G→A missense mutation in the gene that caused replacement of arginine by a glutamine at position 36 (R36Q) in the C domain of the corresponding IGF-1 protein. This change decreased the binding affinity of IGF-1 for IGF-1R by nearly three-fold, but normal affinity for IGFBP-3 was maintained [18,19]. This study confirmed that IGF-1 mutations that lead to only partial loss of IGF-1 protein activity can cause significant postnatal as well as prenatal growth defects. While high-dose hGH therapy (400 mcg/kg/week) promoted successful catch-up growth, the patient’s treatment modality was recently changed to rhIGF-1 therapy [20]. It should be noted that rhIGF-1 therapy has only been approved by the US FDA to treat patients with severe primary IGF-1 deficiency or patients with GH gene deletions who have developed neutralizing antibodies to GH [21]. The genotype-phenotype correlations and response to hGH therapy for each of these patients expressing IGF-1 mutations is summarized in Table 2 [11,13,16-18].

**IGF-1R**

Various compound heterozygous mutations throughout the coding sequence of IGF-1R have been described for multiple families, with each case exhibiting phenotype variations [22]. Typically, IGF-1R mutations can be classified as point mutations or partial deletions. When one patient born SGA with significantly delayed postnatal growth was evaluated for IGF-1R mutations, investigators determined that two point mutations in exon 2 of IGF-1R caused two single-base pair substitutions in the codons for amino acid 108 (CGG→CAG) and 115 (AAA→AAC) of the corresponding protein. This change resulted in two-thirds-lower binding affinity of IGF-1 to IGF-1R in fibroblasts as compared with controls. When treated with hGH therapy (37.5 mcg/kg/week), the patient’s growth rate was increased to the 75th percentile for her age [23].

Similarly, a second patient born SGA who suffered from postnatal growth delay, microcephaly, and mild mental retardation was evaluated for IGF-1R mutations.

| Genetic mutation | Phenotype | GH response | Ref. |
|------------------|-----------|-------------|-----|
| Deletion of exons 4 and 5 | Birth weight −3.9 SD; birth length −5.4 SD; sensorineural deafness and mental retardation; nearly undetectable IGF-1 levels | − | Woods, 1996 [11] |
| Truncated version of exon 6 | Birth weight −4 SD; birth length −6.5 SD; sensorineural deafness and mental retardation; low serum IGF-1 levels | − | Bonapace, 2003 [13] |
| V44M | Birth weight −3.9 SD score; birth length −4.3 SD score; bilateral hearing loss, microcephaly, severe mental retardation; elevated GH levels and IGF-1 levels but normal IGFBP-3 levels | n.a. | Walenkamp, 2005 [16] Denley, 2005 [17] |
| R36Q | Birth weight −2.5 SD score; birth length −3.7 SD score; mild mental development delay; reduced IGF-1 levels but increased IGFBP-3 levels | + | Netchine, 2006 [18] |

hGH, human growth hormone; IGF-1, insulin-like growth factor-1; IGFBP-3, insulin-like growth factor binding protein-3; n.a., not available; SD, standard deviation.
A heterozygous point mutation CGA to TGA (Arg59-Ter) in exon 2 of IGF-1R caused early termination of transcription of the IGF-1R protein, leading to reduced receptor expression on the cell surface, as well as decreased autophosphorylation and phosphorylation of signaling proteins [23]. When treated with hGH at 30 mcg/kg/day starting at age 6 years, the patient’s height increased by 1.01 SD after two years of therapy, indicating that hGH therapy can improve quality of life for SGA patients with this mutation [24].

When 24 children born SGA were evaluated by direct sequencing of IGF-1R to identify causal mutations, two patients were observed to have a heterozygous missense mutation (C→T) of IGF-1R, which altered the cleavage site of the proreceptor of IGF-1R from RLRR to RLQR (R709Q). This mutation inhibited the expression of mature IGF-1R from the IGF-1R precursor protein. Interestingly, the two patients who presented with this mutation had different levels of mental development. While patient 1 displayed mental retardation, patient 2 had normal intellectual development. Thus, no link exists between the heterozygous IGF-1R mutation and intellectual development [25].

Similarly, two more patients were evaluated and determined to present with a missense mutation in the intracellular kinase domain of IGF-1R. The older patient, a 35-year-old mother, showed above-average intelligence and no dysmorphic features, but her height (~4.0 SD score) and head circumference (~3.0 SD score) showed growth retardation. Her daughter, patient 2, was born SGA and showed normal mental development but delayed motor development by the age of 15 months. Both patients showed increased IGF-1 levels. Sequence analysis of IGF-1R showed a heterozygous IGF-1R mutation and intellectual development [25].

In addition to point mutations, distal deletions of the terminal long arm of chromosome 15 have also been linked to patients born SGA, although these mutations are quite rare. Often, these patients present with symptoms resembling Prader-Willi or Angelman syndrome, two diseases resulting from deletions in the 15q11q13 region [30]. One patient born SGA who exhibited continued growth retardation at the age of 4.5 years was evaluated for such distal deletion. It was determined that the patient presented with partial monosomy 15q26.2→15qter, correlating to a deleted critical region of approximately 5.7 Mb [31]. This deletion includes the region 15q26.3, to which the IGF-1R gene has been assigned [32]. A similar deletion was observed for a patient born SGA who displayed a heterozygous 8.58 Mb deletion in the same region [33]. Similarly, a patient born SGA who showed significant growth retardation by the age of 2 years was evaluated for deletions in chromosome 15. Results indicated that the maternally derived chromosome 15 had a 4.7 Mb deleted region, which included 15q26.2 [34]. The smallest deletion of chromosome 15 that has been observed to cause SGA birth involves a mutation in exons 11–21 of the IGF-1R gene (a 0.095 Mb deletion) and was associated with SGA births over three generations in a single family [35]. Typically, patients with partial deletions in this region display mental and psychomotor developmental retardations more often than patients with point IGF-1R mutations [22].

Finally, a patient born SGA with high IGF-1 levels who showed only marginal improvement in height following treatment with hGH therapy at the age of 7.4 years (doses ranging from 31 to 36 mcg/kg/day) was evaluated for IGF-1R mutation. Gene sequencing showed heterozygous T→A mutation at position 1886, which resulted in substitution of valine with glutamic acid at position 599 of the protein (V599E). This mutation interfered with the receptor trafficking pathway, diminishing the density of the receptor on the cell surface [29]. The genotype-phenotype correlations and response to hGH therapy for each of these patients expressing IGF-1R point mutations is summarized in Table 3 [23,25-29].
Acid-Labile Subunit (ALS) Deficiency

In serum, IGF-1 circulates in complex with IGFBP-3 or IGFBP-5 and an ALS, an 85-kDa glycoprotein that functions to prolong the half-life of the IGF-IGFBP-3/IGFBP-5 binary complex [38]. Sixteen different mutations of the IGFLS gene, located at 16p13.3 on chromosome 16, have been observed in patients who presented with reduced postnatal growth. The type of IGFLS gene mutation varies, including missense, nonsense, deletion, duplication and insertion that cause frameshift and premature stop codons, and in-frame duplication mutations, but nearly all of the mutations show autosomal recessive pattern of inheritance and cause defects in the leucine-rich repeat region of the corresponding ALS protein (Table 4) [39-47]. All of these mutations result in circulating ALS levels that are barely detectable based on enzyme-linked immunosorbent assay, radioimmunoassay, or Western immunoblot assays, indicating that the mutations likely inhibit the corresponding protein from being secreted by the liver or cause the protein to degrade rapidly after secretion. The circulating ALS deficiency results in a severe reduction in IGF-1 and IGFBP-3 levels, insulin insensitivity, and pubertal delay. hGH therapy was initiated for some of these patients in an effort to increase growth rate. However, despite the treatments, ranging in duration from six months to more than two years, very little growth response was observed. However, it has been suggested that hGH therapy may be beneficial for heterozygous carriers who still carry one intact IGFLS allele.

Select polymorphisms

Obesity and diabetes

For many individuals born SGA, health concerns such as obesity, type 2 diabetes, hypertension, and ischemic heart disease are often encountered later in life [48-50]. In one study, DNA samples from 546 patients (227 children born SGA and 319 born AGA) were analyzed for 54 single nucleotide polymorphisms (SNPs) associated with diabetes or obesity. Genetic variations in five of these SNPs (KCNJ11, BDNF, Table 4 Genetic mutations involved in ALS deficiency [39-47]

| Genetic mutation | Type of mutation | Homozygous/Heterozygous |
|------------------|-----------------|------------------------|
| E35KfsX87        | Frameshift, premature stop codon | Homozygous |
| E35GfsX17        | Frameshift, premature stop codon | Heterozygous |
| G605             | Missense, premature stop codon | Homozygous |
| P73L             | Missense | Compound heterozygous |
| L134Q            | Missense | Homozygous |
| L172F            | Missense | Homozygous |
| A183SfsX149      | Frameshift, premature stop codon | Compound heterozygous |
| S195_R197dup     | In-frame insertion of 3 amino acids, SLR | Compound heterozygous |
| L241P            | Missense | Compound heterozygous |
| L244F            | Missense | Compound heterozygous |
| N276S            | Missense | Homozygous |
| Q320X            | Nonsense | Homozygous |
| L437_L439dup     | In-frame insertion of 3 amino acids, LEL | Homozygous |
| D440N            | Missense | Homozygous |
| L497fsX40        | Frameshift, premature stop codon | Homozygous |
| C540R            | Missense | Compound heterozygous |

ALS, acid-labile subunit.
PFK PTER, and SEC16B) correlated with SGA size. Therefore, genetic factors that contribute to obesity and type 2 diabetes likely correlate with SGA [51].

Angiotensinogen gene variants
Angiotensinogen (AGT) is an α2-globulin precursor to angiotensin II that regulates blood pressure and overall homeostasis [52]. In one study, 174 women and their 162 infants born SGA were compared with 400 women and their 240 infants born AGA. The study evaluated these individuals for a methionine to threonine substitution at codon 235 (235Met > Thr) in the AGT gene, a mutation associated with pregnancy complications such as preeclampsia [53]. The results showed a higher frequency of the 235Thr allele in both mothers (0.60 for SGA versus 0.36 for controls) and infants (0.59 for SGA versus 0.38 for controls) who were associated with SGA births [54]. However, the mechanism by which the 235Met > Thr mutation affects maternal-placental and fetal-placental circulation and, consequently, fetal growth is not understood. Interestingly, a prior study found no correlation between this polymorphism and an increased risk of SGA birth. The differences between the findings of the two investigations were attributed, in part, to variation in ethnic diversity between the two study groups [55].

Deletion of exon 3 growth hormone receptor (d3-GHR)
The d3-GHR polymorphism, a 2.7 kbp deletion in exon 3 of the GHR gene, is a common genetic defect in individuals with normal height and those born SGA [56]. However, for patients born SGA, the d3-GHR polymorphism has been investigated as a potential mutation that affects hGH therapy due to its role in GH signaling. When response to hGH therapy was compared between children born SGA who had only full-length GHR versus at least one d3-GHR allele, results showed that patients with the d3-GHR polymorphism responded 1.7 to 2 times better to hGH therapy than patients with only the full-length gene [57]. Similarly, SGA patients with either two full-length GHRs (fl/fl) or one (d3/fl) or two (d3/d3) d3-GHR alleles were administered hGH for 12 months at a mean dose of 56 ± 11 mcg/kg/day. At the end of 12 months, carriers of either one or two d3-GHR alleles were observed to respond slightly better to hGH therapy than patients with two full-length alleles, although the difference was not statistically significant. The authors suggested that response to hGH therapy for patients with this mutation depends on the specific causes of short stature, such as IGF-1 insensitivity or IGF-1 deficiency [58]. Consequently, children born SGA with the d3-GHR mutation appear to be prime candidates for hGH therapy, although these results are still controversial.

For instance, a comparison was made between the GHR genotype (ie, fl/fl, d3/fl, or d3/d3) of patients with GH deficiency and the individual’s response to hGH treatment. Patients were treated with hGH at a mean dose of 0.2 mg/kg/week for one year and then evaluated for height SD score, height velocity, and height velocity SD score. No statistically significant difference with respect to the measured outcomes could be observed between the patients with the d3-GHR allele and patients who were homozygous for the full-length GHR. Furthermore, this study observed that there was no relationship between an individual’s baseline phenotype and his/her GHR genotype, suggesting that the d3-GHR allele does not affect height in GH deficiency [59]. This lack of correlation between d3-GHR genotype and response to hGH treatment was also confirmed in studies for patients born SGA [60,61].

Recently, a meta-analysis of 15 studies investigating the effects of d3-GHR genotype and a patient’s first-year response to hGH therapy, including height gain and change in growth velocity, was conducted. The results of this analysis indicated that patients with the d3-GHR allele showed improved growth velocity when treated with hGH therapy, but the treatment outcome was affected by the dose (low doses of hGH showed best response) and age at time of treatment (older patients responded more favorably). It should be noted, however, that this meta-analysis did not discriminate with respect to the cause of short stature [62]. In a recent 3-year review, Doerr et al. conclude that the determination of GHR isoforms for deletion of exon 3 is not particularly useful in defining the overall response to GH in short SGA children [63].

Uniparental disomy (UPD) and imprinting effects
UPD is a process whereby a person inherits two copies of a gene or chromosome from one parent and no copies from the other parent. In most cases, UPD does not affect fetal development. However, if a UPD gene is also an imprinted gene, there may be adverse effects to the fetus, because UPD of imprinted genes is equivalent to functional nullisomy [64]. The transcriptional regulation of imprinted genes varies from normal genes in that imprinted genes are only active from one parent allele. For instance, a gene may be active only when paternally inherited; the paternal allele of this gene is “switched off.” Conversely, imprinted genes can be maternally expressed and paternally imprinted [65]. Thus, if a patient inherits two versions of an imprinted gene (eg, two copies of a maternal, “switched-off” gene), phenotype abnormalities may result. Studies have indicated that several UPDs can be responsible for short stature in patients born SGA.

SRS
SRS is a disorder characterized by reduced birth weight, facial features including triangular shape and pointed chin, and body asymmetry [66,67]. Growth restrictions continue through life and often correlate with fasting
hypoglycemia [68]. hGH treatment, given daily as subcutaneous injections at a dose of 35 mcg/kg/day for up to three years, is usually suggested for these patients [69].

The genetic causes of SRS vary, with cases of autosomal-dominant, autosomal-recessive, and X-linked inheritance all observed (as reviewed by Hitchins and Abu-Amero) [68,70]. However, the most referenced causal candidates for this disease involve mutations on chromosomes 7 and 11, which both contain groups of genes that undergo genomic imprinting [68]. Since the early 1990s, maternal uniparental disomy 7 (mUPD7), both full mUPD7 and mUPD for the long arm of chromosome 7, were documented to be the cause of SRS in approximately 10% of cases [71]. However, the phenotype of an SR patient presenting UPD7 cannot be predicted, as the exact etiology of the mutation varies [72]. Polymerase chain reaction with microsatellite repeat markers or Southern blot analysis with variable number of tandem repeats can effectively be used to screen patients for mUPD7 [73].

In addition to mUPD7, the imprinted region on chromosome 11p15 has been associated with SRS in up to 65% of patients. Specifically, hypomethylation at the imprinting center region 1 (ICR1) was associated with fetal growth retardation in SRS patients (Figure 1) [74,75]. Generally, the ICR1 region regulates the expression of IGF2 and H19, and loss of methylation of this region is associated with approximately 50% of SRS cases [68]. However, an inherited duplication (0.76 – 1 Mb) in the ICR2 domain of 11p15 has also been shown to be involved in the etiology of SRS. The duplicated region included the maternally expressed genes KCNQ1, CDKN1C, TSSC5/SLC22A8 and TSSC3/PHDLA2 and the paternally expressed gene LIT1 [76]. It should be noted, however, that the distribution of methylation values among patients with SRS is quite varied, making clinical diagnosis of the disease based on methylation analysis difficult [77]. In general, use of hGH has become a standard treatment regimen for patients with SRS, despite the limited number of evaluations regarding the effectiveness of this treatment [78].

mUPD

UPD of the long arm of chromosome 14 (UPD14) has been associated with both below-average growth and mental retardation. Initially, it was not known whether the congenital anomalies present in UPD14 patients resulted from an extra copy of an active imprinted gene (ie, two genes that were “switched on”) or the absence of gene expression caused by the presence of two repressed alleles (ie, two genes “switched off”). To determine the likely cause of the phenotype, patients with distal partial trisomy for chromosome 14 (Ts14) were evaluated to determine genotype-phenotype correlations to determine whether the partial trisomy was of maternal or paternal origin. By investigating patients with an extra copy of either maternally inherited or paternally inherited copies of chromosome 14, the investigators hoped to observe more pronounced effects of the disease if it was caused by active imprinted genes. All 13 patients with distal maternal Ts14 (mTs14) were born SGA. Conversely, over half of the patients with paternal Ts14 (pTs14) were born at weights AGA, indicating that an absence of paternal information likely causes growth retardation in patients with UPD14. The minimum trisomic regions 14q31.1-14qter and 14q24.3-14qter were identified as possibly containing the imprinted genes [79]. Overall, the phenotype of patients with mUPD14 can be quite variable. A review of 24 cases of patients displaying mUPD14 attributes the growth retardation of these patients to confined placental mosaicism and imprinted genes that cause early skeletal maturation, although unusual phenotypes may also be caused by autosomal, recessively inherited mutations [80].

hGH treatment for SGA

Much research has correlated genetic mutations with SGA births, but the ability to predict the effectiveness of hGH therapy for each mutation remains controversial. Table 5 summarizes the various mutations that have been shown to cause SGA and the likelihood that hGH therapy will promote growth for individuals with these mutations [11,13,16-18,23,25-29,39-47,51,53-55,57-62,68,70,74-76,78-80]. Some patients with IGF-1 mutations have shown positive growth catch-up when treated with hGH therapy, while others have shown better response to rhIGF-1 therapy. Alternatively, the response to hGH therapy for patients with IGF-1R mutations appears to correlate with the type of mutation; patients with distal deletions of the

![Figure 1 Quantitative representation of methylation indices for H19-IGF2 ICR1 in individuals with SRS (individuals 1–9 and individual 6’s twin) and an individual with isolated hypermethylation of the H19 promoter (BWS1). Five individuals with SRS displayed partial loss of H19-IGF2 ICR1, indicated by the bar below the shaded area near 50%. SRS, Silver-Russell syndrome. Reprinted from [74] with permission from Macmillan Publishers Ltd; copyright 2005.]
**Table 5 Summary of known genetic causes of SGA and the correlating response to hGH therapy [11,13,16-18,23, 25-29,39-47,51,53-55,57-62,68,70,74-76,78-80]**

| Class of genetic mutation | Specific genetic variant | Response to hGH therapy |
|---------------------------|--------------------------|-------------------------|
| GH/IGF-1 axis             | IGF-1                    | Generally not effective |
|                           | IGF-1R                   | Good for partial distal deletions; generally not effective for point mutations |
|                           | Point                    |                         |
|                           | Distal                   |                         |
| ALS deletions             |                          | Good outcome for heterozygous carriers |
| Select Polymorphisms      |                          |                         |
|                           | Obesity/diabetes-related genes | Unclear |
|                           | Angiotensinogen gene     | Unclear |
|                           | d3-GHR                   | Good outcome, but dose and age matter |
| SRS                       |                          | hGH therapy is commonly used for SRS, but correlation between effectiveness and specific genetic mutation has not been carefully evaluated |
| UPD/imprinting effects    | mUPD7                    |                         |
|                           | Full mUPD7               |                         |
|                           | mUPD7 for long arm of chromosome 7 |                         |
|                           | Hypomethylation at ICR1 on 11p15 |                         |
|                           | Duplication of ICR2 on 11p15 |                         |
| UPD14                     |                          | Unclear |

ALS, acid-labile subunit; ICR, imprinting control region; IGF-1, insulin-like growth factor-1; d3-GHR, deletion of exon 3 growth hormone receptor; hGH, human growth hormone; SGA, small for gestational age; SRS, Silver-Russell syndrome; UPD, uniparental disomy.

*IGF-1R* gene generally have improved GH-induced catch-up growth as compared with patients who have *IGF-1R* point mutations. Finally, the ability to predict the effectiveness of hGH treatment depending on the specific disease (eg, children with SRS versus children with UPD14) has not been thoroughly reviewed, possibly because a significant number of patients born SGA who undergo hGH therapy are never genetically diagnosed. However, despite the controversies, clinical studies have successfully elucidated some trends about hGH treatment on growth in children born SGA (as reviewed by Simon et al [81] and Saenger et al [1]).

The rate of catch-up growth promoted by hGH therapy in patients born SGA correlates with the dose; higher doses typically afford rapid height increase, although a similar response can be achieved using lower doses for a longer time. For instance, a height gain of 2 SD was achieved for patients born SGA using doses of either 67 mcg/kg/day over 2.5 years or 33 mcg/kg/day over 5.5 years (Figure 2A) [82]. However, the low-dose regimen requires three times as many injections and 50% more hGH overall than the high-dose method. The method of administration of hGH therapy can also affect height gain, though less significantly than dose. Patients who received discontinuous high-dose hGH therapy (67 mcg/kg/day for one or two years) have shown slightly increased height gain compared with patients receiving a continuous low-dose regimen (33 mcg/kg/day doses for three or four years), although discontinuation of the treatment typically corresponds with reduction in growth velocity [83]. A similar trend was observed previously by De Zeghers et al, who found that after six years,
height SD scores were similar for high-dose hGH course for two years and continuous low-dose hGH treatment for six years (Figure 2B) [82].

In addition to the dose and method of administration, the age of initiation of hGH therapy significantly affects the outcome. Patients treated before the onset of puberty achieve optimal results. A recent study showed that children treated for one year with hGH therapy before the age of 4 years achieved greater height gain (1.7 SD score, 12.5 cm) than those treated after 4 years of age (1.2 SD score) [84]. Even among older patients, this trend persists. Patients receiving hGH therapy more than two years before puberty showed increased height gain (1.7 SD, ~12 cm) compared with patients treated fewer than two years before puberty (0.9 SD gain, 6 cm). However, nearly 90% of these patients achieved adult height within the normal range [85]. Conversely, patients treated during puberty achieved height gain of only 0.6 SD score, and fewer than 50% of these patients achieved normal adult height [86].

In 2003, Ranke et al developed a model that essentially summarized the trends that we have described and that could be used by physicians to individualize hGH treatment for SGA patients. Using a pharmacoepidemiological survey of 613 children, various trends were elucidated. In fact, the model could be used to explain approximately 50% of the variability associated with hGH therapy response during the first and second years of treatment. Nearly 35% of the variability could be attributed to the dose, followed by the patient’s age at the start of treatment. Subsequent growth during the second year of treatment could be predicted based on a successful first year of treatment [87].

It must be mentioned, though not stressed, that some controversy regarding the use of hGH arose in 2011 due to results from a study conducted in France, the Santé Adulte GH Enfant (SAGhE) study. The results from this study indicated that long-term use of hGH in children with short stature could increase a patient’s risk of death [88]. The SAGhE study reported that hGH therapy, when administered to patients at doses above 50 mcg/kg/day, increased the risk of death by 30% as compared to the general population in France. This effect was attributed to the dose, followed by the patient’s age at the start of treatment. Subsequent growth during the second year of treatment could be predicted based on a successful first year of treatment [87].

It must be mentioned, though not stressed, that some controversy regarding the use of hGH arose in 2011 due to results from a study conducted in France, the Santé Adulte GH Enfant (SAGhE) study. The results from this study indicated that long-term use of hGH in children with short stature could increase a patient’s risk of death [88].

### Table 6 Use of hGH therapy in SGA children in the United States and Europe

| Age at start of (year) | FDA-approved indication in 2001 | EMEA-approved indication in 2003 |
|------------------------|-------------------------------|-------------------------------|
| Height SDS at start     | Not stated                    | Height SDS > 1 SD below midparental height SDS |
| Growth velocity         | No catch-up growth            | Less than 0 SD for age         |
| Reference to            | Not stated                    |                                |
| midparental            |                               |                                |
|                        |                               |                                |
| Dose                    |                               |                                |
| (mcg/kg/day)            |                               |                                |
| 70                     |                               | 35                             |

**FDA**, United States Food and Drug Administration; **EMEA**, European Agency for the Evaluation of Medicinal Products; **hGH**, human growth hormone; **SDS**, standard deviation score; **SGA**, small for gestational age.

Reprinted with permission from [1].

### Conclusions

Based on results from more than 20 years of research, numerous genetic causes for SGA births have been realized. Genetic defects in either IGF-1 or IGF-1R that result in SGA size typically correlate with phenotypical features such as microcephaly and mental retardation. The most predictive factors for IGF-1R deletion include small birth size, head size, and stature, as well as high IGF-1 levels, developmental delay, and micrognathia. hGH therapy in patients with mutations in IGF-1 has shown moderate success. Furthermore, for patients with IGF-1R mutations, hGH treatment has been shown to be especially promising, particularly for those with distal deletions of the terminal long arm of chromosome 15. Overall, in studies in which the genotype of SGA patients was not known and hGH therapy was conducted, improvements were observed for most of the patient population, particularly if therapy was begun at a young age.

However, despite these positive results, a number of questions regarding the effectiveness of the treatment remain. For instance, hGH therapy for children with SRS has shown positive results, but overall the improvements are often not statistically significant. Furthermore, the differences in SGA patient response to hGH therapy are still only slightly understood. While much of the diversity in response rates to hGH therapy for SGA patients correlates with the type of genetic mutation, the role of additional factors, such as ethnicity, on this treatment still requires significant research.

### Abbreviations

(AGA): Appropriate for gestational age; (AGT): Angiotensinogen; (ALS): Acid-labile subunit; (FDA): Food and Drug Administration; (GH): Growth hormone; (ICR1): Imprinting center region 1; (IGFBP-3): Insulin-like growth factor binding protein-3; (IGF): Insulin-like growth factor; (IGF-1R): Insulin-like growth factor-1 receptor; (mUPD7): Maternal uniparental disomy 7; (hGH): Recombinant human GH; (hIGF-1): Recombinant human IGF-1; (SAGhE): Santé Adulte GH Enfant study; (SGA): Small for gestational age;
(SD): Standard deviation; (SRS): Silver-Russell syndrome; (Ts14): Trisomy for chromosome 14; (UPOD): Uniparental disomy; (US): United States.

Competing interests
Dr. Saenger reports that he receives grant support from Novo Nordisk Inc., and that he is a consultant for LG and Biopartners. Dr. Reiter reports that he has received payment from Novo Nordisk Inc. for board membership; from Abbott Pharmaceuticals as a consultant; from Quintiles for development of educational presentations, and from various pharmaceutical companies for lectures, including service on speakers bureaus.

Authors’ contributions
The authors contributed equally to this work and were involved in the development of its concept, outline, and narrative. At all stages, the authors discussed the data presented and commented on the manuscript. Both authors read and approved the final manuscript.

Acknowledgments
The authors would like to thank Meredith A. Mintzer, PhD, and Emma Hitt, PhD, of MedVal Scientific Information Services, LLC, for providing medical writing and editorial assistance. This manuscript was prepared according to the International Society for Medical Publication Professionals’ Good Publication Practice for Communicating Company-Sponsored Medical Research: The GPP2 Guidelines. Funding to support the preparation of this manuscript was provided by Novo Nordisk Inc.

Author details
1Albert Einstein College of Medicine, Winthrop University Hospital, 120 Mineola Boulevard, Mineola, NY 11501, USA. 2Baystate Children’s Hospital, Tufts University School of Medicine, 759 Chestnut Street Springield, MA 01199, USA.

Received: 6 October 2011 Accepted: 19 March 2012 Published: 15 May 2012

References
1. Saenger P, Czenichow P, Hughes I, Reiter EO: Small for gestational age: short stature and beyond. Endocr Rev 2007, 28(2):219–251.
2. Clayton PE, Canfaran S, Czenichow P, Johansson G, Rapaport R, Rogol A: Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab 2007, 92(3):804–810.
3. Lee PA, Chenrek SD, Hokken-Koelega AC, Czenichow P: International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24–October 1, 2001. Pediatrics 2003, 111(6 Pt 1):1253–1261.
4. Arna AD: Small for gestation and growth hormone therapy. Indian J Pediatr 2006, 73(1):73–78.
5. Rapaport R, Tuermo T: Growth and growth hormone in children born small for gestational age. Acta Paediatr 2005, 94(10):1348–1355.
6. Hediger ML, Overpeck MD, Maurer KR, Czuczkarni RJ, McGlynn A, Davis WW: Growth of infants and young children born small or large for gestational age: findings from the Third National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med 1998, 152(1):125–131.
7. Karlberg J, Albertsson-Wikland K: Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr Res 1995, 38(5):733–739.
8. Hokken-Koelega AC, De Riddere MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL: Children born small for gestational age: do they catch up? Pediatr Res 1995, 38(2):267–271.
9. The Growth Genetics Consortium. Available at http://www.growthgeneticsconsortium.org/index.shtml Accessed February 15, 2012.
10. Le Roth D: Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 1997, 336(9):638–640.
11. Woods KA, Camacho-Hubner C, Savage MO, Clark AZ: Intratuberine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996, 335(18):1363–1367.
12. Woods KA, Camacho-Hubner C, Bergman RN, Barter D, Clark AJ, Savage MO: Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 2000, 85(4):1407–1411.
13. Bonapace G, Concimino D, Formisola S, Stransiglio P: A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. J Med Genet 2008, 45(12):917–919.
14. Coutinho DC, Coleta RR, Costa EM, Pachi PR, Boguszewski MC, Damiani D, Mendonca BB, Amhuld U, Jorge AA: Polymorphisms identified in the upstream core polyadenylation signal of IGF1 gene exons 6 do not cause pre- and postnatal growth impairment. J Clin Endocrinol Metab 2007, 92(12):4889–4892.
15. van Gemund JJ, Laurent de Angelo MS, van Gelderen HH: Familial prenatal dwarfism with elevated serum immuno-reactive growth hormone levels and end-organ unresponsiveness. Maandchr Kindergeneesk 1970, 37(1):2–38.
16. Walekamp MJ, Kerperen M, Pereira AM, Hilhorst-Hofstee Y, van Doorn J, Chen JW, Mohan S, Denley A, Forbes B, van Duyvenvoorde HA, van Thiel SW, Slummers CA, Bax JJ, de Laat JA, Breuning MB, Romijn JA, Witt JM: Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab 2005, 90(5):2855–2864.
17. Denley A, Wang CC, McNeil KA, Walekamp MJ, van DH, Witt JM, Wallace JC, Norton RS, Kerperen M, Forbes BE: Structural and functional characteristics of the Val44Met insulin-like growth factor I missense mutation: correlation with effects on growth and development. Mol Endocrinol 2005, 19(3):711–721.
18. Netchine I, Azzi S, Houang M, Seurin D, Perin L, Ricort JM, Daubas C, Legay E, Czernausek SD: IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003, 349(23):2211–2222.
19. Netchine I, Azzi S, Le Bouc Y, Savage MO: IGF1 molecular anomalies demonstrate its critical role in fetal, postnatal growth and brain development. Best Pract Res Clin Endocrinol Metab 2011, 25(1):181–190.
20. Gaul Al, Prous Jr: The year’s new drugs. Drug News Perspect 2005, 19 (1):33–53.
21. Klummt J, Kiess W, Paffele R: IGF1R mutations as cause of SGA. Best Pract Res Clin Endocrinol Metab 2011, 25(1):191–206.
22. Abuzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, Kiess W, Klummt J, Kratzsch J, Osgood D, Perin L, Ricort JM, Daubas C, Legay E, Czernausek SD: IGF-I receptor mutations demonstrating the critical role of IGF-I in growth and brain development. J Pediatr 2006, 149(4):656–664.
23. Abuzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, Kiess W, Klummt J, Kratzsch J, Osgood D, Paffele R, Raile K, Seidelberg B, Smith RJ, Czernausek SD: IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003, 349(23):2211–2222.
24. Raile K, Klummt J, Schneider A, Keller A, Laue S, Smith R, Paffele R, Kratzsch J, Kiess W: Clinical and functional characteristics of the human Arg59Ter insulin-like growth factor I receptor (IGF1R) mutation: implications for a gene dosage effect of the human IGF1. J Clin Endocrinol Metab 2006, 91(6):2264–2271.
25. Kawashima Y, Kanaki S, Yang F, Kinoshita T, Hanaki K, Nagashii J, Ohtsuka Y, Hitatome I, Ninomoya H, Nanba E, Fukushima T, Takahashi S: Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation. J Clin Endocrinol Metab 2005, 90(8):4679–4687.
26. Walekamp MJ, van der Kamp HJ, Pereira AM, Kant SG, van Duyvenvoorde HA, Kruthof MF, Breuning NH, Romijn JA, Kerperen M, Witt JM: A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin-like growth factor-I receptor. J Clin Endocrinol Metab 2006, 91(9):3362–3370.
27. Inagaki K, Tulpakov A, Rubtsov P, Sverdlova P, Petkova V, Yakar S, Terekhov S, LeRoith D: A familial insulin-like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization. J Clin Endocrinol Metab 2007, 92(1):1542–1548.
28. Kruis T, Klummt J, Galli-Tsinopoulou A, Walborn T, Schlicke M, Muller E, Kratzsch J, Koner A, Odeh R, Kiess W, Paffele R: Heterozygous mutation within a kinase-conserved motif of the insulin-like growth factor I
receptor causes intrauterine and postnatal growth retardation. J Clin Endocrinol Metab 2010, 95(3):1137–1142.

29. Wallborn T, Muller S, Kramm J, Kraus T, Kratzsch J, Schmidt G, Schlicke M, Muller E, van de Leur H, Kess W, Paffen R: A heterozygous mutation of the insulin-like growth factor-I receptor causes retention of the nascent protein in the endoplasmic reticulum and results in intrauterine and postnatal growth retardation. J Clin Endocrinol Metab 2010, 95(3):1235–1244.

30. Knoll JH, Nichols RD, Magenis RE, Graham JM Jr, Lalande M, Last SA: Angelman and Prader-Willi syndromes share a common chromosome 15 deletion but differ in parental origin of the deletion. Am J Med Genet 1989, 32(2):285–290.

31. Pinson L, Perrin A, Plouzenec C, Parent P, Metz C, Collet M, Le Bris MJ, Douet-Guilbert N, More P, de Breucker N: Detection of an unexpected subtelomeric 15q26.2–qter deletion in a little girl: clinical and cytogenetic studies. Am J Med Genet A 2005, 138A(2):160–165.

32. Peoples M, Ratlouvic F, Francke U: Hemizygosity at the insulin-like growth factor I receptor (IGF1R) locus and growth failure in the ring chromosome 15 syndrome. Cytogenet Cell Genet 1995, 70(3–4):228–234.

33. Choi JH, Kang M, Kim GH, Hong M, Jin HY, Lee BH, Park JY, Lee SM, Seo EJ, Saenger and Reiter 33. Ester WA, van Duyvenvoorde HA, Boot AM, Kant SG, White SJ, Losekoot M, den Dunnen JT, Karperien M, Wit JM: De novo subtelomeric 15q26.2–qter deletion detected by satellite translocation in a child with developmental delay and severe growth retardation. Am J Med Genet A 2007, 143B(271–276).

34. Vaneen CA, Eussen HJ, Govaerts LC, de Kort SW, Oulink RJ, Wouters CH, Holken-Koelga AC, de Klein A: Phenotype-genotype correlation in a familial IGF1R microdeletion case. J Med Genet 2010, 47(7):492–498.

35. Walenckam MJ, de Muinck Keizer-Schrama SM, de Mos M, Kalf ME, van Duyvenvoorde HA, Boot AM, Kant SG, White SJ, Losekoot M, den Dunnen JT, Karperien M, Wit JM: Successful long-term growth hormone therapy in a girl with haploinsufficiency of the insulin-like growth hormone factor-I receptor due to a terminal 15q26.2–qter deletion in patients with intrauterine growth retardation and postnatal catch-up growth failure. J Clin Endocrinol Metab 2011, 96(1):E130–E134.

36. Grijalbandez R, Botia AM, Prascorszt W, Sripo T, Dissaneevate P, Permsirivanich W, Limproatir P: De novo subtelomeric deletion of 15q associated with satellite translocation in a child with developmental delay and severe growth retardation. Am J Med Genet 2007, 143B(271–276).

37. Veenn CA, Eussen HJ, Govaerts LC, de Kort SW, Oulink RJ, Wouters CH, Holken-Koelga AC, de Nein A: Phenotype-genotype correlation in a familial IGF1R microdeletion case. J Med Genet 2010, 47(7):492–498.

38. Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT: Deficiency of the circulating insulin-like growth factor I receptor due to a terminal 15q26.2–qter deletion detected by multiplex ligation probe amplification. J Clin Endocrinol Metab 2008, 93(6):2421–2425.

39. Ester WA, van Duyvenvoorde HA, de Wit CC, Broekman AJ, Ruvenkamp CA, Govaerts LC, Wit JM, Holken-Koelga AC, Losekoot M: Two short children born small for gestational age with insulin-like growth factor 1 receptor haploinsufficiency. J Clin Endocrinol Metab 2009, 94(12):4717–4722.

40. Wczasliwski WP, Ueki I, Wang J, Du GT: The acid-labile subunit (ALS) of the 150kDa IGF-Binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 2001, 170(1):63–70.

41. Domene HM, Hwa V, Jasper HG, Rosenfeld RG: Acid-labile subunit (ALS) deficiency. Best Pract Res Clin Endocrinol Metab 2011, 25(1):101–113.

42. Domene HM, Bengoava SA, Martinez AS, Ropelato MG, Pennisi P, Scaglia P, Heinrich JJ, Jasper HG: Deficiency of the circulating insulin-like growth hormone factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004, 350(6):570–577.

43. Domene HM, Scaglia PA, Lteif A, Mahmud FH, Kimman S, Frystyk J, Bedecarrats P, Gutierrez M, Jasper HG: Phenotypic effects of null and haploinsufficiency of acid-labile subunit in a family with two novel IGFALS gene mutations. J Clin Endocrinol Metab 2007, 92(11):4444–4450.

44. Heath KE, Argente J, Barrios V, Pozo J, az-Gonzalez F, Martos-Moreno GA, Caimari M, Gracia R, Campos-Barros A: A primary acid-labile subunit deficiency due to recessive IGFALS mutations result in postnatal growth deficit associated with low circulating insulin growth factor (IGF-I, IGF binding protein-3 levels, and hyperinsulinemia. J Clin Endocrinol Metab 2008, 93(5):1616–1624.

45. van Duyvenvoorde HA, Kerspers MJ, Twickler TB, van Doorn J, Genier VJ, Noordam C, Losekoot M, Karperien M, Wit JM, Hermus AR: Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit. Eur J Endocrinol 2008, 159(2):113–120.

46. Fofanova-Gambetti Ov, Hwa V, Kinch S, Pihoker C, Chiu HK, Hogler W, Cohen LE, Jacobsen C, Derr MA, Rosenfeld RG: Three novel IGFALS gene mutations resulting in total ALS and severe circulating IGF-IGFBP-3 deficiency in children of different ethnic origins. Horm Res 2005, 71(2):100–110.
Submit your manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• No space constraints or color figure charges
• Global visibility
• Full support for open accession numbers

Submit your manuscript at www.biomedcentral.com/submit

doi:10.1186/1687-9856-2012-12
Cite this article as: Saenger and Reiter: Genetic factors associated with small for gestational age birth and the use of human growth hormone in treating the disorder. International Journal of Pediatric Endocrinology 2012:12.